Drug Trial Radar · NCT00796900
Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)
Last checked: Nov 19, 2026Latest source record: May 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
34
Planned (sponsor's estimate)
Start
May 2008
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- Medical University of ViennaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 24, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Dantrolene is used to prevent hyperthermia in intensive care patients suffering from subarachnoidal hemorrhage.
Conditions
- Hyperthermia
Interventions
DantroleneDrug
Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
PlaceboDrug
Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Magnitude and Duration of HyperthermiaTime frame: 8 hours, every 10 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University Vienna
Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.